Cure51
Artificial Intelligence · Drug Discovery AI
Overview
Cure51 collects and analyses the biological data of exceptional cancer survivors to find what made their outcome possible. Its platform combines a global clinical network with multi-omics data science. The company is headquartered in Paris.
Funding and backers
Total raised
$16.2M
1 round on record
Latest round
$16.2M
Seed · Mar 2024 · 2 yr ago
Backers
2
Hitachi Ventures, Sofinnova Partners
The money's age
Long since its last round
31 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
2 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Tractionpublic signals, read monthly
Web presence
top 8%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Seed | Mar 2024 | $16.2M | — | PRNewswire |
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
The Biological Computing Co. (TBC) turns discoveries from real neurons into software that makes AI faster and cheaper, without retraining.
Pathos integrates AI technology, biological modeling, and the largest collection of oncology patient data to make clinical trials smarter…
Relation Therapeutics is a London biotechnology company founded in 2019 that applies graph machine learning to disease biology. Its…
Accelerate your research with Pluto Bio. The collaborative platform for multi-omics data management, analysis, and visualization.
Causaly is the fastest way to find evidence, explore hidden connections and make new predictions in biomedical science. The company…
Latent Labs builds generative models that design proteins from a natural language description of the desired function. Founded in 2023 by a…
Financials
Total raised
$16.2M
Latest round
Seed
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Seed | 2024 | $16.2M | Details |
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Hitachi VenturesVia a fund
Sofinnova PartnersVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Cure51 Launches NHS-Approved Study With Cambridge University Hospitals and Seven Other Leading UK Oncology Institutions to Unlock Cancer Survival Secrets
Read more
Report
Cure51 raises a €15M seed round aiming to crack the code on cancer survival
Rather than grimly assembling data about cancer deaths to predict outcomes in treatment, the founders of Cure51 had another idea: Instead, the company assembles data about long-term survivors of cancer, hoping to crack the code on what keeps people alive.
Read more
Report
Cure51: €15 Million Secured To Advance Biological Mechanisms For Survivors Among Cancer Patients
Cure51 - a biotech company looking to unlock the biological mechanisms responsible for exceptional survivors among cancer patients - announced it has successfully raised €15 million in a seed funding round led by Sofinnova Partners. Other investors in thi
Read more
Report
Cure51 raises a €15 million seed round to harness the natural power of cancer survivors to develop first-in-class treatments and transform cancer into a curable disease
/PRNewswire/ -- Cure51, a techbio company seeking to unlock the biological mechanisms responsible for exceptional survivors among cancer patients, today...
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Paris
France
HQ